Company mounts defence as it reveals treatment generated $873m in third-quarter revenue
Home/FT/Gilead insists remdesivir improves Covid-19 survival rates FT Gilead insists remdesivir improves Covid-19 survival rates Financial Times0 Less than a minute Facebook X LinkedIn Company mounts defence as it reveals treatment generated $873m in third-quarter revenue Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Share on WhatsApp (Opens in new window) WhatsApp Email a link to a friend (Opens in new window) Email Related Financial Times0 Less than a minute Facebook X LinkedIn Facebook X LinkedIn Tumblr Pinterest Reddit VKontakte Share via Email Print